Pilomatrical Carcinoma
Pilomatrical carcinoma (also called pilomatrix carcinoma) is a rare malignant adnexal tumor that differentiates toward hair matrix cells. It can arise de novo from undifferentiated germinative cells, or develop through malignant transformation of a long-standing benign calcifying epithelioma (pilomatricoma).
Accumulation of Concurrent Mutations (CTNNB1 + TP53/CDKN2A)
- Activation of the Wnt/beta-catenin pathway: Like benign pilomatricoma, pilomatrical carcinoma carries a gain-of-function mutation in exon 3 of the CTNNB1 gene. Beta-catenin builds up in the nucleus and activates the transcription factor LEF-1.
- A second malignant hit (second-hit event): The key difference is the addition of further tumor suppressor mutations. Inactivation of TP53 (loss of p53 function), mutation or deletion of CDKN2A (loss of p16INK4a), and TERT promoter mutations disable programmed cell death (apoptosis). Instead of maturing into benign shadow cells, the basaloid cells keep dividing abnormally without limit.
Invasive Behavior and Metastatic Potential
- Loss of cadherin adhesion and stromal invasion: Tumor cells express less membrane E-cadherin and secrete more matrix metalloproteinases (MMP-2, MMP-9). This lets them break through the laminin-5 basement membrane and invade deep into the muscle fascia, the subcutaneous fat, and the sheaths of nearby nerves (perineural invasion, PNI).
- Risk of distant spread: About 10–15% of cases spread through the lymphatics to regional lymph nodes or through the bloodstream to the lungs, bones, and liver.
Histopathologic Criteria
Microscopic Features (H&E)
Unlike benign pilomatricoma, which has a well-defined fibrous capsule, pilomatrical carcinoma shows an abnormal, destructive architecture:
- Infiltrative asymmetric lobules: The tumor lobules have ragged borders and push through the dermal–subcutaneous junction down to the muscle fascia.
- Nuclear atypia and atypical mitoses: Basaloid cells predominate, with enlarged nuclei, irregular nuclear membranes, prominent nucleoli, and numerous atypical mitotic figures, including multipolar mitoses.
- Central necrosis with nuclear dust (comedo-like necrosis): Rather than an orderly transition to shadow cells, the centers of the lobules often show coagulative necrosis with leftover nuclear debris, mixed with bands of shrunken shadow cells and scattered calcium granules.
Imaging and High-Frequency Ultrasound
- High-frequency skin ultrasound:
- A large hypoechoic mass with irregular, finger-like borders (spiculated/infiltrative margins) and no protective fibrous capsule.
- Color Doppler signal: Marked blood vessel growth within the tumor, with a high peak systolic velocity (PSV) and low resistive index (RI), reflecting malignant neovascularization.
- MRI / CT scan: Required for large tumors (> 2 cm) of the head and neck to assess invasion of the periosteum, facial muscles, and nerves.
Clinical Presentation
- Epidemiology: In contrast to the benign form seen in children, pilomatrical carcinoma mostly affects older men (over 50–70 years), with a male-to-female ratio of 3:1.
- Common sites: The head, face, and neck (> 70%), especially the scalp, behind the ears, the cheeks, and the neck.
- How it develops:
- A subcutaneous mass or nodular papule that grows quickly over a few months, often reaching a large size (2.0–10.0 cm).
- The overlying skin is red, swollen, and lumpy, readily ulcerates and bleeds, and is firmly fixed to deeper structures (fascia, bone).
Mohs Surgery (MMS) and Multidisciplinary Management at Haute-Derma
Because local recurrence is very high (50–60%) after conventional excision, the gold-standard treatment for pilomatrical carcinoma at Haute-Derma is Mohs micrographic surgery (MMS), combined with sentinel lymph node biopsy (SLNB) when indicated.
Confirmatory Biopsy and Staging Imaging
- Incisional biopsy: Takes the full thickness from the epidermis down to the subcutaneous fat to assess the depth of invasion and the Ki-67 proliferation index.
- Imaging to check for spread:
- MRI of the head and neck to assess how deeply the tumor invades bone or muscle.
- Ultrasound of neck lymph node levels I–V; if a node looks enlarged, fine-needle aspiration (FNA) is performed.
- CT of the chest and abdomen to rule out distant spread to the lungs and liver.
Mohs Micrographic Surgery (MMS): The Gold Standard for Removing Malignant Tumors
- The Mohs surgeon outlines the tumor and removes the first layer with a narrow 2–3 mm safety margin.
- The specimen is mapped and color-coded for orientation, flash-frozen, and sectioned horizontally so the entire deep and peripheral margin can be examined (100% margin evaluation).
- The slides are read under the microscope while the patient waits. If cancer cells remain at any point on the map, the surgeon returns to exactly that spot and removes another thin layer, repeating until the margins are completely free of tumor (clear margins).
- When conventional wide local excision (WLE) is used: If Mohs surgery is not possible, a wide safety margin of 1.0–2.0 cm from the tumor edge is required, extending down through the underlying muscle fascia.
Cosmetic Reconstruction and Adjuvant Radiotherapy
- Reconstructing the defect (reconstructive surgery): Once the margins are confirmed 100% clear, the wound is closed with local rotation flaps or transposition flaps.
- Adjuvant radiotherapy: Recommended when:
- The tumor shows perineural invasion (PNI+).
- The tumor has invaded the periosteum or deep fascia and no further margin can be taken.
- Tumor cells remain at the margins after several Mohs stages.
- Follow-up schedule: Dermatology and oncology visits every 3 months for the first 2 years, then every 6 months after that, to catch any local recurrence or lymph node spread early.
